Mechanisms of tumor escape: Role of tumor microenvironment in inducing apoptosis of cytolytic effector cells

Archivum Immunologiae et Therapiae Experimentalis

Volumn 54, Issue 5, 2006, Pages 323-333

  Poggi, Alessandro ^a,c   Zocchi, Maria Raffaella ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Apoptosis; Natural cytotoxicity receptor; NKG2D; Soluble HLA I; Stromal cells; Tumor escape

Indexed keywords

CD8 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSFORMING GROWTH FACTOR BETA;

AMINO ACID METABOLISM; APOPTOSIS; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOLYSIS; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; NATURAL KILLER T CELL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; HUMANS; INTERFERON TYPE II; KILLER CELLS, NATURAL; MACROPHAGES; NEOPLASMS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 33750290402     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-006-0038-7     Document Type: Review

References (113)

1. Aggarwal S. and Pittenger M. F. (2005): Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105, 1815-1822.
2. Alleva D. G., Burger C. J. and Elgert K. D. (1993): Interferon-gamma reduces tumor-induced macrophage-mediated suppression: role of prostaglandin-E2 and tumour necrosis factor-alpha. Immunopharmacology, 25, 215-227.
3. Augello A., Tasso R., Negrini S. M., Amatesi A., Indiveri F., Cancedda R. and Pennesi G. (2005): Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed cell death 1 pathway. Eur. J. Immunol., 35, 1482-1490.
4. Badovinac V. P., Porter B. B. and Harty J. T. (2002): Programmed contraction of CD8+ T cells after infection. Nat. Immunol., 3, 619-626.
5. Bakker A. B., Phillips J. H., Figdor C. G. and Lanier L. L (1998): Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J. Immunol., 160, 5239-5245.
6. Bauer S., Groh V., Wu J., Steinle A., Phillips J. H., Lanier L. L. and Spies T. (1999): Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MIC-A. Science, 285, 727-729.
7. Beatty G. L. and Paterson Y. (2000): IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J. Immunol., 165, 5502-5508.
8. Bellone G., Aste-Amegaza M., Trinchieri G. and Rodeck U. (1995): Regulation of NK cell functions by TGF-β1. J. Immunol., 155, 1066-1073.
9. Bennett M. W., O'Connell J., O'Sullivan G. C., Brady C., Roche D., Collins J. K. and Shanahan F. (1998): The Fs counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoima. J. Immunol., 160, 5669-5675.
10. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., Galum E. and Rachmilewitz J. (2005): Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood, 105, 2214-2219.
11. Bogdan C. (2001): Nitric oxide and the immune response. Nat. Immunol., 2, 907-916.
12. Borsi L., Alemanni G., Gaggero B. and Zardi L. (1996): Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed cells. Int. J. Cancer, 29, 632-635.
13. Bossi G. and Griffths G. M. (1999): Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med., 5, 90-96.
14. Bronte V. and Zanovello P. (2005): Regulation of immune responses by 1-arginine metabolism. Nat. Rev. Immunol., 5, 641-654.
15. Bronte V., Kasic T., Gri G., Gallana K., Borsellino G., Marigo I., Battistini L., Iafrate M., Prayer-Galetti T., Pagano F. and Viola A. (2005): Anti-tumour responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med., 201, 1257-1268.
16. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N. P. and Zanovello P. (2000): Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood, 96, 3838-3846.
17. Cabrera T., Lopez-Nevot M. A., Gaforio J. J., Ruiz-Cabello F. an Garrido F. (2003): Analysis of HLA expression in human tumor tissue. Cancer Immunol. Immunother., 52, 1-9.
18. Chang C. I., Liao J. C. and Kuo L. (2001): Macrophage arginase promotes tumor cell growth and suppress nitric oxide mediated cytotoxicity. Cancer Res., 61, 110-1106.
19. Chao C. C., Sandor M. and Dailey M. O. (1994): Expression and regulation of adhesion molecules by gammadelta T cells from tissues and intestinal epithelium. Eur. J. Immunol., 24, 3180-3187.
20. Chappell D. B. and Restifo N. P. (1998): T cell-tumor cell: a fatal interaction? Cancer Immunol. Immunother., 47, 65-71.
21. Chaux P., Moutet M., Faivre J., Martin F. and Martin M. (1996): Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of T cell activation. Lab. Invest., 74, 975-983.
22. Chouaib S., Thiery J., Gati A., Guerra N., El Behi M., Dorothee G., Mami-Chouaib F., Bellet D. and Caignard A. (2002): Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens, 60, 273-281.
23. Colleuori D. M. and Ash D. E. (2001): Classical and slow-binding inhibitors of human type II arginase. Biochemistry, 40, 9356-9362.
24. Contreras D. N., Krammer P. H., Potkul R. K., Bu P., Rossi J. L., Kaufmann A. M., Gissmann L. and Qiao L. (2000): Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J. Immunther., 23, 67-74.
25. Cosman D., Mullberg J., Sutherland C. L., Chin W., Armitage R., Fanslow W., Kubin M. and Chalupny N. J. (2001): ULBPs, novel MHC class-I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity, 14, 123-133.
26. Davel L. E., Jasnis M. A., de la Torre E., Gotoh T., Diament M., Magenta G., Sacerdote de Lustig E. and Sales M. E. (2002): Arginine metabolic pathways involved in the modulation of tumour-induced angiogenesis by macrophages. FEBS Lett., 532, 216-220.
27. De Santo C., Serafini P., Marigo I., Dolcetti L., Bolla M., Del Soldato P., Melani C., Guiducci C., Colombo M. P., Iezzi M., Musiani P., Zanovello P. and Bronte V. (2005): Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. USA, 102, 4185-4190.
28. De Waal Malefyt R., Abrams J., Bennett B., Figdor C. G. and de Vries J. E. (1991): Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes-an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med., 174, 1209-1220.
29. Diehl L., den Boer A. T., Schoenberger S. P., van der Voort E. I., Schumaker T. N., Melief C. J., Offringa R. and Toes R. E. (1999): CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T lymphocyte tolerance and augments anti-tumour vaccine efficacy. Nat. Med., 5, 774-779.
30. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P. D., Matteucci P., Grisanti S. and Gianni A. M. (2002): Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99, 3838-3843.
31. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noel D. and Iorgensen C. (2003): Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood, 102, 3837-3844.
32. Dolstra H., Fredrix H., van der Meer A., de Witte T., Figdor C. and van de Weil-van Kemenade E. (2001): TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant., 27, 1087-1093.
33. Dunn G. P., Bruce A. T., Ikeda H., Old L. J. and Schreiber R. D. (2002): Cancer immunoediting from immunosurveillance to tumor escape. Nat. Immunol., 3, 991-998.
34. Fallarino F., Grohmann U., Hwang K. W., Orabona C., Vacca C., Bianchi R., Belladonna M. L., Fioretti M. C., Alegre M. L. and Puccetti P. (2003): Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol., 4, 1206-1212.
35. Ferrarini M., Consogno G., Rovere P., Sciorati C., Dagna L., Resta D., Rugarli C. and Manfredi A. A.(2001): Inhibition of caspases maintains the antineoplastic function of gammadelta T cells repeatedly challenged with lymphoma cells. Cancer Res., 61, 3092-3095.
36. Ferrarini M., Ferrero E., Dagna L., Poggi A. and Zocchi M. R. (2002): Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol., 23, 14-18.
37. Ferrero E., Fabbri M., Poggi A., Galati G., Bernasconi S. and Zocchi M. R. (1998): Tumor-driven matrix invasion by infiltrating lymphocytes: involvement of the α1 integrin I-domain. Eur. J. Immunol., 28, 2530-2536.
38. Fisch P., Meuer E., Pende D., Rothenfusser S., Viale O., Kock S., Ferrone S., Fradelizi D., Klein G., Moretta L., Rammensee H. G., Boon T., Coulie P. and van der Bruggen P. (1997): Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. Eur. J. Immunol., 12, 3368-3379.
39. Fontenot J. D., Rasmussen J. P., Gavin M. A. and Rudensky A. Y. (2005): A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol., 6, 1142-1151.
40. Fontenot J. D. and Rudensky A. Y. (2005): A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol., 6, 331-337.
41. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U. and Ferrara G. B. (2002): Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med., 196, 459-468.
42. Fujihara T., Yashiro M., Inoue T., Sawada T., Kato Y., Ohira M., Nishiguchi Y., Ishikawa T., Sowa M. and Chung K. H. (1999): Decrease in ICAM-1 expression on gastric cancer cells is correlated with lymphnode metastasis Gastric Cancer, 2, 221-225.
43. Garcia-Lora A., Algarra I. and Garrido F. (2003): MHC class I antigen, immune surveillance and tumour immune escape. J. Cell Physiol., 195, 346-355.
44. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., Elkum N., Alshabanah M., Bin Amer S., Tulbah A., Ajarim D., Al-Tweigeri T. and Dermime S. (2006): The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 3, 190-198.
45. Groh V. R., Rhinehart H., Secrist S., Bauer K. Grabstein H. and Spies T. (1999): Broad tumor-associated expression and recognition by tumor-derived gammadelta T cells of MIC-A and MICB. Proc. Natl. Acad. Sci. USA, 96, 6879-6884.
46. Groh V., Steinle A., Bauer S. and Spies T. (1998): Recognition of stress-induced MHC molecules by intestinal epithelial gammadeltaT cells. Science, 279, 1737-1740.
47. Groh V., Wu J., Yee C. and Spies T. (2002): Tumor-derived soluble MIC ligands impair expression of NKG2D and cell activation. Nature, 419, 734-738.
48. Grothey A., Heistermann P., Philippou S. and Voigtmann R. (1998): Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumor stage. Br. J. Cancer, 77, 801-807.
49. Grohmann U., Orabona C., Fallarino F., Vacca C., Calcinaro F., Falorni A., Candeloro P., Belladonna M. L., Bianchi R., Fioretti M. C. and Puccetti P. (2002): CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol., 3, 1097-1101.
50. Horwitz E. M., Gordon P. L., Koo W. K., Marx J. C., Neel M. D., McNall R. Y., Muul L., Hofmann T. (2002): Isolated allogeneic bone-marrow derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc. Natl. Acad. Sci. USA, 99, 8932-8937.
51. Hunter C. A. (2005): New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol., 5, 521-531.
52. Kagi D. Lederman B., Burki K., Zinkernagel R. M. and Hengartner H. (1996): Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol., 14, 207-232.
53. Kawada H., Fujita J., Kinjo K., Matsuzaki Y., Tsuma M., Miyatake H., Muguruma Y., Tsuboi K., Itabashi Y., Ikeda Y., Ogawa S., Okano H., Hotta T., Ando K. and Fukuda K. (2004): Non-hematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood, 104, 3581-3587.
54. Kopfstein L. and Christofori G. (2006): Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol. Life Sci., 63, 449-468.
55. Jinushi M., Takehara T., Tatsumi T., Kanto T., Groh V., Spies T., Kimura R., Miyagi T., Mochizuki K., Sasaki Y and Hayashi N. (2003): Expression and role of MIC-A and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int. J. Cancer, 104, 354-361.
56. Ljunggren H. G. and Karre K. (1990): In search of the "missing self": MHC molecules and NK cell recognition. Immunol. Today, 11, 237-244.
57. Lanier L. L. (1998): NK cell receptors. Annu. Rev. Immunol., 16, 359-393.
58. Lazarus H. M., Haynesworth S. E., Gerson S. L., Rosenthal N. S. and Caplan A. I. (1995): Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant., 16, 557-564.
59. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassam M., Uzunel M. and Ringden O. (2004): treatment of severe acute graft-versus host disease with third party haploidentical mesenchymal stem cells. Lancet, 363, 1439-1441.
60. Leishman A. J., Naidenko O. V., Attinger A., Koning F., Lena C. J., Xiong Y., Chang H. C., Reinhertz E., Kronenberg M. and Cheroutre H.. (2001): T cell responses modulated through interaction between CD8alphaalpha and the non classical MHC class I molecule, TL. Science, 294, 1936-1939.
61. Li B., Bessiri H., Rossman M. D., Kramer P., Eyuboglu A. F., Torres M., Sada E., Imir T. and Carding R. S. (1998): Involvement of the Fas/Fas ligand pathway in activation-induced cell death of mycobacteria-reactive human gammadelta T cells: a mechanism for the loss of gammadelta T cells in patients with pulmonary tuberculosis. J. Immunol., 161, 1558-1567.
62. Long E. O. (1999): Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol., 17, 875-904.
63. + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 90, 516-525
64. Malmberg K.-J. (2004): Effective immunotherapy against cancer. Cancer Immunol. Immunother., 53, 879-892.
65. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W. and Dilloo D. (2004): Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103, 4619-4621.
66. Mellor A. L. and Munn D. H. (2004): IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol., 4, 762-774.
67. Moretta A., Bottino C., Vitale M., Pende D., Biassoni R., Mingari M. C. and Moretta L. (1996): Receptors for HLA-class I molecules in human natural killer cells. Annu. Rev. Immunol., 14, 619-648.
68. Moretta A, Bottino C., Vitale M., Pende D., Cantoni C., Mingari M. C., Biassoni R. and Moretta L. (2001): Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol., 19, 197-223.
69. Munn D. H., Shafizadeh E., Attwood J. T., Bondarev I., Pashine A. and Mellor A. L. (1999): Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med., 189, 1363-1372.
70. Nagata S. (1997): Apoptosis by death factor. Cell, 88, 355-365.
71. Nestle F. O., Farkas A. and Conrad C. (2005): Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol., 17, 163-169.
72. Otsuji M., Kimura Y., Aoe T., Okamoto Y. and Saito T. (1996): Oxidative stress by tumor-derived macrophages suppresses the expression of CD3z chain of T-cell receptor complex and antigen-specific T-cell response. Proc. Natl. Acad. Sci. USA, 93, 13119-13124.
73. Pawelec G. (2004): Tumor escape: antitumor effectors too much of a good thing? Cancer Immunbiol. Immunother., 53, 262-274.
74. Pende D., Rivera P., Marcenaro S., Chien-Chung C., Biassoni R., Conte R., Kubin M., Cosman D., Ferrone S., Moretta L. and Moretta A. (2002): Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytoxicity. Cancer Res., 62, 6178-6186.
75. Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., Mororman M. A., Simonetti D. W., Craig S. and Marshak D. R. (1999): Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
76. Poggi A., Carosio R., Fenoglio D., Brenci S., Murdaca G., Setti M., Indiveri F., Scabini S., Ferrero E. and Zocchi M. R. (1999): Migration of Vdelta1 and Vdelta2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat. Blood, 103, 2205-2213.
77. Poggi A., Massaro A.-M., Negrini S., Contini P. and Zocchi M. R. (2005): Tumor-induced apoptosis of human IL2-activated natural killer cells. Role of natural cytotoxicity receptors. J. Immunol., 174, 2653-2660.
78. Poggi A., Massaro A.-M., Negrini S., Pierri I., Balocco M., Michelis G., Equino S., Albarello A., Gobbi M. and Zocchi M. R. (2004): Evidence for killing of mesenchymal stem cells (MSC) by autologous lymphocytes. blood (ASH Annual Meeting Abstracts), 104, 1290.
79. Poggi A., Prevosto C., Massaro A.-M., Negrini S., Urbani S., Pierri I., Saccardi R., Gobbi M. and Zocchi M. R. (2005): Interaction between human natural killer cells and bone marrow stromal cells induces NK cell triggering. Role of NKp30 and NKG2D receptors. J. Immunol., 175, 6352-6360.
80. Poggi A., Venturino C., Castellani S., Clavio M., Miglino M., Gobbi M., Steinle A.,Ghia P., Stella S., Caligaris Cappio F. and Zocchi M. R. (2004): Vδ1 T lymphocytes from B-CLL patients recognise ULBP3 expressed on leukemic B cells and upregulated by transretinoic acid. Cancer Res., 64, 9172-9179.
81. + T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II. J. Immunol., 168, 6071-6077.
82. + T lymphocytes from healthy donors and multiple sclerosis patients. J. Immunol., 162, 4349-4354.
83. Potian J. A., Aviv H., Ponzio N. M., Harrison J. S. and Rameshawar P. (2003): Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol., 171, 3426-3434.
84. Plumas J., Chaperot L., Richard M. J., Molens J. P., Bensa J. C. and Favrot M. C. (2005): Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia, 19, 1597-1604.
85. Rathmell J. C. and Thompson C. B. (1999): the central effectors of cell death in the immune system. Annu. Rev. Immunol., 17, 781-828.
86. Refaeli Y., Parijs L. V., Alexander S. I. and Abbas A. K. (2002): Interferon-γ is required for the activation-induced death of T lymphocytes. J. Exp. Med., 196, 999-1005.
87. Rivoltini L., Carrabba M., Huber V., Castelli C., Novellino L., Dalerba P., Mortarini R., Arancia G., Anichini A., Fais S. and Parmiani G. (2002): Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev., 188, 97-113.
88. Rosenberg S. A., Yang J. C. and Restifo N. P. (2004): Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 10, 909-915.
89. Saio M., Radoja S., Marino M. and Frey A. B. (2001): Tumor-infiltrating macrophages induce apoptosis in activated CD8+ T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol., 167, 5583-5593.
90. Sakaguchi S. (2004): Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol., 22, 531-562.
91. Sakaguchi S. (2005): Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol., 6, 345-352.
92. Salih H. R., Antropius H., Gieseke F., Lutz S. Z., Kanz L., Rammensee H. G. and Steinle A. (2003): Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood, 102, 1389-1396.
93. Salih H. R., Rammensee H. G. and Steinle A. (2002): Cutting edge: down-regulation of MIC-A on human tumors by proteolytic shedding. J. Immunol., 169, 4098-5102.
94. Schimielau J. and Finn O. J. (2001): Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppressor of T-cell function in advanced cancer patients. Cancer Res., 61, 4756-4760.
95. Sekiya I., Larson B. L., Smith J. R., Pochampally R., Cui J. G. and Prockop D. J. (2002): Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells, 20, 530-541.
96. + suppressor T cells: more questions than answers. Nat. Rev. Immunol., 2, 389-400.
97. Steeber D. A. and Tedder T. F. (2001): Adhesion molecule cascades direct lymphocyte recirculation and migration during inflammation. Immunol. Res., 22, 299-317.
98. Sotsios Y. and Ward S. G. (2000): Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines. Immunol. Rev., 177, 217-235.
99. Spaggiari G. M., Contini P., Carosio R., Arvigo M., Ghio M., Oddone D., Dondero A., Zocchi M. R., Puppo F., Indiveri F. and Poggi A. (2002): Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8. Evidence for a negative regulation exerted by CD94/NKG2A complex and KIR2D. Blood, 99, 1706-1714.
100. Spaggiari G. M., Contini P., Dondero A., Carosio R., Puppo F., Indiveri F., Zocchi M. R. and Poggi A. (2002): Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood, 100, 4098-4107.
101. Spaggiari G. M., Contini P., Negrini S., Dondero A., Carosio R., Ohio M., Puppo F., Indiveri F., Zocchi M. R. and Poggi A. (2003): IFN-gamma production in human NK cells through the engagement of CD8 by soluble or surface HLA class I molecules. Eur. J. Immunol., 33, 3049-3059.
102. Spaggiari G. M., Capobianco A., Becchetti S., Mingari M. C. and Moretta L. (2006): Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107, 1484-1490.
103. Trinchieri G. (1989): Biology of natural killer cells. Adv. Immunol., 47, 187-376.
104. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T. and Van den Eynde B. J. (2003): Evidence for a tumoural immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med., 9, 1269-1274.
105. Vig M., Srivastava S., Kandpal U., Sade H., Lewis V., Sarin A., George A., Bal V., Durdik J. M. and Rath S. (2004): Inducible oxide nitric synthase in T cells regulates T cell death and immune memory. J. Clin. Invest., 113, 1734-1742.
106. Von Boehmer H. (2005): Mechanisms of suppression by suppressor T cells. Nat. Immunol., 6, 338-343.
107. Wajant H. (2002): The Fas signalling pathway: more than a paradigm. Science, 296, 1635-1636.
108. Woodbury D., Schwarz E. J., Prockop D. J. and Black I. B. (2000): Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res., 61, 364-370.
109. Zea A. H., Rodriguez P. C., Atkins M. B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J. and Ochoa A. C. (2005): Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res., 65, 3044-3048.
110. Zocchi M. R. and Poggi A. (1993): Lymphocyte-endothelial cell adhesion molecules at the primary tumor site in humans. J. Natl. Cancer Inst., 85, 246-247.
111. Zocchi M. R. and Poggi A.(1993): Adhesion of lymphocytes to vascular endothelium in LAD syndrome: possible contribution of N-CAM. Immunol. Today, 14, 94-95.
112. Zocchi M. R., Contini P., Alfano M. and Poggi A. (2005): Pertussis toxin (PTX) B subunit and the non-toxic PTX mutant PT9K/129G inhibit TAT-induced TGF-β production by NK cells and TGF-β-mediated NK cell apoptosis. J. Immunol., 174, 6054-6061.
113. Zocchi M. R. and Poggi A. (2004): Role of gammadelta T lymphocytes in tumor defense. Frontiers Biosci., 9, 2588-2604.